PATENT COOPERATION TRE. Y

From the INTERNATIONAL BUREAU

PCT

NOTOTICATION CONCERNING TRANSMITTAL OF COPY OF INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (CHAPTER LOFTILE PATENT COOPERATION TREATY)

(PCT Rule 44his Inch

3 o.

Los Angeles, GA 90017-2586

ETATS UNIS D'AMERIQUE

LEVY, Seth. D. Davis Wright Tremaine LLP 865 Figueroa Street Suite 2400

Dae of estiling alapment/years 26 January 2006 (26.01.2006)

20 3810419 2000 (20.01.2000

IMPORTANT NOTICE

Spilication specification for a spilication of the spilication for a polication for a polic

International filting date (Jaconson Jones 15 July 2004 (15.07 2004)

Priority dust: day/decorlage ur1 15 July 2003 (15:07-2003)

Applicant

CEDARS-SINAI MEDICAL CENTER of all

The International Buttern transmus intervals a copy of the international preliminary report on patentiability (Citainer Lot the Fatent Cooperation Transm.)

RECEIVED

Davis Wright Tremaine LLP

FEB 1 4 2006

ATTYS TOWNS

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

See item 4 below

(PCT Rule 44his)

FOR FURTHER ACTION

nternational PCT/US200	application No. 04/022827	International (iling date (day/month/year) 15 July 2004 (15.07.2004)	Priority date (day/month/year) 15 July 2003 (15.07.2003)
	Patent Classification (8 at information in Form	th edition unless older edition indicated) PCT/SA/237	
pplicass	INAI MEDICAL CENT	779	
EDANSIG	INAL WEDICAL DEN	CO	
		y report on patentability (Chepter I) is issued by to ority under Rule 44 bis.1(a).	the International Bureau on behalf of the
2. This	REPORT consists of a	otal of 5 sheets, including this cover sheet.	
		ference to the written opinion of the International are report on patentability (Chapter I) instead.	Searching Authority should be read as a reference
10 110	c sitternasional faciations	by report on patentarinty (compact to dismost.	
3. This	roport contains indicate	ons relating to the following items:	
	Bex No. 1	Basis of the report	
	Box No. II	Priority	
	Box No. III	Non-establishment of opinion with regard applicability	to novelty, inventive step and industrial
	Box No. IV	Lack of unity of invention	
	Bux No. V	Reasoned statement under Article 35(2) w applicability, citations and explanations so	ith regard to novelty, inventive step or industrial apporting such statement
	Box No. VI	Certain documents eited	
	Box No. VII	Certain defects in the international applica	tion
	Box No. VIII	Certain observations on the international a	pplication
	P00000		
		,	
		I communicate this report to designated Offices i	in accordance with Rules 44bis.3(c) and 93bis.1 b. hefore the expiration of 30 months from the prior

Date of issuance of this report 16 January 2006 (16.01.2006) Amborized officer The International Bureau of WIPO 34, chemin des Colombettes 12/1 Geneva 20, Switzerland Yolaine Cussac Telephone No. +41 22 338 70 80 Facsimile No. +41 22 740 14 35

Applicant's or agent's file reference

67789-269

PATENT COOPERATION TREATY

Tong the NTERNATIONAL SEARC	CHING AUTH	ORITY	7	WIPO 26 JAN
To: SETH D. LEVY PILLSBURY WINTHROF LLP 725 SOUTH FIGUEROA STREET, SUITE 2800 LOS ANGELES, CA 90017-5406			PCT	
				(PCT Rule 43bis.1)
			Date of mailing	9.4.IAN 2005
Applicant's or agent's file	reference		FOR FURTHER	
				See paragraph 2 below
081476-0310561 International application N	ło.	International filing dat	te (day/month/year)	Priority date (day/month/year)
		15 July 2004 (15.07.2	004)	15 July 2003 (15.07.2003)
PCT/US04/22827 International Patent Class	fication (IPC)	er both national classifi	cation and IPC	
IPC(7): C12N 5/00 and U				•
Applicant	0 (11. 94.05)	<u> </u>	***************************************	
CEDARS-SINAI MEDIC	AT CENTER			
CEDARA-MINISTER	THE CONTRACT			
1. This opinion contains	indications rel	iating to the following it	ens:	
Box No. I	Basis of the	e opinion		
Box No. II	Priority			
Box No. III	Non-establi	stiment of opinion with	regard to novelty, inv	entive step and industrial applicability
Box No. IV	Lack of un	ity of invention		
Box No. V	Reasoned s applicabilit	tatement under Rule 43i y; citations and explana	bis,1(a)(i) with regard tions supporting such (to novelty, inventive step or industrial statement
Box No. VI	Certain doc	numents cited		
Box No. VII	Certain def	sets in the international	application	
Box No. VIII	Certain obs	ervations on the interna	tional application	
2. FURTHER ACTIO	ON			
International Prelimb	nary Examinit this one to be		n IPEA has notified the	be considered to be a written opinion of the s not apply where the applicant chooses an se fine-trational Bureau under Rule 66.1bis(b) dered.
IPEA a written reply mailing of Form PCI	r together, wi 7ISA/220 or b	ere appropriate, with a efore the expiration of 2		PEA, the applicant is invited to submit to the the expiration of 3 months from the date of iority date, whichever expires later.
For further options, 5	ee Form PCT/	ISA/220.		
3. For further details, se	e notes to Por	m PCT/ISA/220.		
Name and mailing address	of the ISA/ U	S	Authorized office	
Mail Sup PCT, A Commissioner for	nn: ISA/US		Sumesh Kaysha	EPh.D. VIVIVIV De CKOO
P.O. Box 1450				The state of the s
Alexandriu, Virgia Facsimile No. (703) 305-3	88 22313-1430. 8230		Telephone No.	DOS DOS

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/22827

	E LE LAND VALLE VIII DE LA CONTRACTOR DE	4 5 2 4 4 4 4 4 4
Box N	I Basis of this opinion	
l. With	gard to the language, this opinion has been established on the bash led, unless otherwise indicated under this item.	of the international application in the language in which
	his opinion has been essablished on the basis of a translation from thich is the language of a translation furnished for the purposes of	the original language unto the following language international search (under Rules 12.3 and 23.1(b)).
ž. Wid clain	egard to any nucleotide and/or amino acid sequence disclosed invention, this opinion has been established on the basis of:	in the international application and necessary to the
2.	ype of material	
	a sequence listing	
	table(s) related to the sequence listing	•
ъ.	ormat of material	
	in written format	
	in computer readable form	
¢.	ine of filing/furnishing	
	contained in international application as filed.	
	. filed together with the international application in computer	readable form.
	furnished subsequently to this Authority for the purposes of s	earch.
3. 🔲	in addition, in the case that more than one version or copy of a Hed or furnished, the required statements that the information in the he application as filed or does not go beyond the application as file	as subsequent or additional cupies is identical to that in
4. Add	nal comments:	

WRITTEN OPINION OF THE

International application No. PCI/US04/22827

аррисаниу, сканова	id explanations supp	orting such statement	ntive step or industrial
1. Statement			
Novelty (N)	Claims	1-8	YES
***************************************		3-10	
			YES
Inventive step (IS)	Claims	9-10	
	Cianna	Z-1X	***************************************
Industrial applicability (IA)	Claims	1-10	
	Claims	NONE	NO
Claims 1-10 meet the criteria set out in PC transdifferentiating monocytes into endoth prior art does not teach or fairly suggest a compound that modulates biological activities the compound that modulates biological activities are to the process of the process	elial ceils by artificially method of modulating n ty of PTN.	increasing the expression of pleiot econscularization in a mammal by	rophin (PTN). In addition the administering to the manural a

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/22827

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the questions whether the claims are fully supported by the description, are made:

Claims 9-10 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because of the claims are not fully supported by the description. The description does not disclose the claimed invention in a manner sufficiently clear and complete for the claimed invention to be carried out by a person skilled in the art because. The disclosure fulls to disclose a compound administration of which modulates necessarilarization in a mammal, wherein the compound inhibits or enhances the biological activity of pleiotrophin (PTN)